Octreotide
1
Reactions 895 - 30 Mar 2002 ★ S Octreotide First report of intestinal perforation in an elderly patient: case report A 75-year-old woman with gastrointestinal symptoms secondary to scleroderma experienced a spontaneous intestinal perforation during treatment with octreotide. The woman reported increased abdominal discomfort and bloating 5 days after starting treatment with SC octreotide 0.5 mg/day. A CT scan revealed a substantial amount of free air in her abdominal cavity, and some dilation of her small and large bowels. Octreotide was discontinued and the woman was treated with IV fluids and antibacterials, and underwent a period of ‘nil by mouth’. Her abdominal symptoms settled quickly. The site of her intestinal perforation was never located. Author comment: ‘It is possible that the intraluminal pressure increase associated with octreotide predisposed to intestinal perforation in this patient with myopathic intestinal pseudo-obstruction and a thin bowel wall due to scleroderma.’ Malcolm A, et al. Intestinal perforation associated with octreotide therapy in scleroderma. American Journal of Gastroenterology 96: 3206-3208, Nov 2001 - Australia 800886769 » Editorial comment: A search of AdisBase and Medline did not reveal any previous case reports of intestinal perforation associated with octreotide. The WHO Adverse Drug Reactions database contained 3 reports of intestinal perforation associated with octreotide. 1 Reactions 30 Mar 2002 No. 895 0114-9954/10/0895-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Octreotide
Reactions 895 - 30 Mar 2002
★ SOctreotide
First report of intestinal perforation in an elderlypatient: case report
A 75-year-old woman with gastrointestinal symptomssecondary to scleroderma experienced a spontaneousintestinal perforation during treatment with octreotide.
The woman reported increased abdominal discomfort andbloating 5 days after starting treatment with SC octreotide 0.5mg/day. A CT scan revealed a substantial amount of free air inher abdominal cavity, and some dilation of her small and largebowels.
Octreotide was discontinued and the woman was treatedwith IV fluids and antibacterials, and underwent a period of ‘nilby mouth’. Her abdominal symptoms settled quickly. The siteof her intestinal perforation was never located.
Author comment: ‘It is possible that the intraluminalpressure increase associated with octreotide predisposed tointestinal perforation in this patient with myopathic intestinalpseudo-obstruction and a thin bowel wall due to scleroderma.’Malcolm A, et al. Intestinal perforation associated with octreotide therapy inscleroderma. American Journal of Gastroenterology 96: 3206-3208, Nov 2001 -Australia 800886769
» Editorial comment: A search of AdisBase and Medline didnot reveal any previous case reports of intestinal perforationassociated with octreotide. The WHO Adverse Drug Reactionsdatabase contained 3 reports of intestinal perforation associatedwith octreotide.
1
Reactions 30 Mar 2002 No. 8950114-9954/10/0895-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
![BS 499 Part 1 [1965]](https://static.fdocuments.nl/doc/165x107/54081862dab5cac8598b460a/bs-499-part-1-1965.jpg)
